Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 24;10(12):2002. doi: 10.3390/vaccines10122002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Individuals with previous SARS-COV-2 infection elicited faster and stronger antibody titers to all types of vaccinations than individuals with no previous infection (naïve). The charts shows waning dynamics in different groups according to previous infection status and vaccine dose. (A) Average anti-spike IgG titers after first vaccination dose in previously infected participants. (B) Average anti-spike IgG titers after first vaccination dose in seropositive participants who never had COVID-19 symptoms. (C) Trajectory of average of anti-spike IgG titers in fully vaccinated individuals (two doses). The grey dashed line in each graph indicates the threshold antibody positivity at 10 AU/mL.